

*cont*²

% to about 20 % of CD34⁺ stem cells, expressed with respect to the total number of progenitor cells.

B
Q3

Amend claim 6 as follows:

--6. (Amended) Cell composition according to claim 2, wherein the macrophages, myeloid cells and the lymphocytes if present, are included in/or generated from blood mononuclear cells.

Q4 *B1*
Amend claim 10 as follows:

--10. (Amended) Process according to claim 8, comprising an additional step of macrophage activation, at the end of the coculture, for instance by addition of γ -interferon or muramyl peptides.

Q5 *B1*
Amend claim 11 as follows:

--11. (Amended) Process according to claim 7, comprising an additional step of concentration of the cells obtained at the end of the coculture, and resuspension in a vehicle suitable for administration to a patient.

Q6 *B1*
Amend claim 13 as follows:

--13. (Amended) Cell composition such as obtained according to the process of claim 7.

Q7

B1
Amend claim 14 as follows:

--14. (Amended) Pharmaceutical composition containing, as active substance, the cell composition according to claim 1.

Amend claim 15 as follows:

B1
A8
~~15. (Amended) Cell composition according to claim 1, characterized by the fact that it is derived from and/or included in a peripheral blood mononuclear cell composition containing:~~

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0,1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells,
- from about 0,1 to about 20% of stem cells.

Amend claim 16 as follows:

T02/9
~~--16. (Amended) Use of a cell composition according to claim 1, for the preparation of drugs, for the restoration of hematopoiesis in an aplastic patient and/or the protection of patients against infectious diseases or against residual tumors.--~~

Add the following new claims:

B2
A10
~~--17. (new) Cell composition according to claim 2, containing T lymphocytes, preferably in a ratio of about 10 to 60% expressed with respect to the total number of cells.~~

~~--18. (new) Pharmaceutical composition containing, as active substance, the cell composition according to claim 2.~~

~~--19. (new) Cell composition according to claim 2, characterized by the fact that it is derived from and/or~~

included in a peripheral blood mononuclear cell composition containing:

and cont

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0,1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells,
- from about 0,1 to about 20% of stem cells.--